Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sofgen Pharma S.A. specializes in the development and manufacturing of specialty pharmaceuticals, with a focus on niche therapeutic areas such as oncology and neurology. The company operates primarily in Europe and North America, leveraging its proprietary drug formulation technologies to differentiate its product offerings.
Sofgen Pharma generates revenue through the sale of specialty and generic drugs, focusing on high-margin products in underserved therapeutic areas. The company's competitive advantages include proprietary drug delivery technologies and established relationships with healthcare providers, which enhance its pricing power.
Approval of new drug applications by regulatory bodies
Market penetration rates in key therapeutic areas
Partnerships or collaborations with larger pharmaceutical companies
Changes in reimbursement policies affecting specialty drugs
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Increased competition from generic drug manufacturers
Potential entry of large pharmaceutical companies into niche markets
Negative equity due to accumulated losses
Liquidity risks stemming from low current ratio
moderate - Sofgen's performance is somewhat tied to healthcare spending, which can be influenced by economic conditions and consumer confidence.
Interest rates affect Sofgen's cost of capital and can influence investment in R&D. Higher rates may compress valuations, impacting stock performance.
minimal - The company operates with a negative debt/equity ratio, indicating low reliance on external financing.
value - Investors may be drawn to the low price/sales ratio and potential for recovery as the company stabilizes.
high - The stock has experienced significant volatility, evidenced by a 98.2% decline over the past year.
